CA2997106C — Lymph directing prodrugs
Assigned to Monash University · Expires 2024-06-04 · 2y expired
What this patent protects
There is provided a compound of the formula (I) and its use, e.g. as a prodrug to promote lymphatic transport and systemic release of a pharmaceutical agent (represented by A in a circle). RI and le independently represent H, or a residue of a C2-C28 fatty acid. ¨X¨ is ¨0¨, ¨ NH…
USPTO Abstract
There is provided a compound of the formula (I) and its use, e.g. as a prodrug to promote lymphatic transport and systemic release of a pharmaceutical agent (represented by A in a circle). RI and le independently represent H, or a residue of a C2-C28 fatty acid. ¨X¨ is ¨0¨, ¨ NH¨ or ¨S¨. ¨L¨ is ¨X'¨. ¨Y¨ represents an optionally substituted ¨Ci-C2a1ky1C(0)R3¨ group or a ¨C2a1keny1C(0)R3¨ or ¨C2a1kyny1C(0)R3¨ group when ¨L¨ is ¨X'¨; R3 is a self-immolative group. X' is 0, S, N(R4) or N(H)S(0)2. R4 is H or C1-C4alkyl.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.